Yuan Zhang, Jingyun Li, Xian Li, Menglin Wang, Xiangli Yang, Li Shi, Zhiwei Cao, Yan Feng, Weiwei Liu, Zhendong Xu, Ruixia Ma, Xiaoping Gao, Wen Liu, Jinmei Xue, Xiaoyong Ren, Xuezhong Li, Xicheng Song, Yi Yang, Fang Quan, Lei Cheng, Weihong Jiang, Huabin Li, Jian Li, Huanhai Liu, Jianfeng Liu, Zheng Liu, Wei Lv, Qianhui Qiu, Xiangdong Wang, Yu Xu, Yuanteng Xu, Qintai Yang, Yucheng Yang, Jing Ye, Hongmeng Yu, Dongdong Zhu, Chengshuo Wang, Luo Zhang
Allergic rhinitis (AR) is a common, persistent nasal disorder that poses significant public health challenges worldwide. Current treatment options frequently fail to achieve adequate symptom control in a substantial subset of patients. Over the past two decades, biologic therapies that target type 2 inflammatory pathways have been used to treat patients experiencing poorly controlled symptoms, despite standard-of-care (SoC) treatment. Although biological treatment options for AR remain limited worldwide, the recent approval of novel agents, such as stapokibart for seasonal allergic rhinitis (SAR), has accelerated clinical research and development in this field. Evidence for biologic therapy in the management of perennial allergic rhinitis (PAR) is currently sparse. To standardise the use of biologics in AR management and promote their evidence-based application, a multidisciplinary expert panel was convened. This position paper evaluates current evidence regarding the efficacy and safety of biologic agents for AR, incorporating data from both international and regional clinical studies. Here, we provide recommendations on appropriate indications for biologic therapy and emphasise its role in patients with uncontrolled SAR, supporting clinical decision-making and facilitating the integration of biologics into routine practice.